Shares of Dr Reddy's Laboratories dropped 6% in early trade on Friday, a day after the company reported a third-quarter profit that fell short of market estimates due to lower sales and pricing pressures in the key North American market.

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market expansions, despite facing price erosion and compliance challenges.

Dr. Reddy's Laboratories shares fell by 6.2% after the company reported a marginal 2% YoY growth in Q3 FY25 net profit to Rs 1,413 crore. Despite robust revenue growth, Jefferies, Nuvama, and DAM Capital have diverse views on the stock,

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The stock closed lower on both BSE and NSE, wiping off a market valuation of Rs 5,399.

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' estimates.

Dr Reddy's Laboratories reported a 2% increase in net profit to Rs 1,413 crore for the third quarter ending December 2024. The company's revenue surged to Rs 8,359 crore, driven by new business acquisitions and launches.

Hyderabad: Despite posting record revenues, pharma major Dr Reddy's Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at 1,